RESUMEN
Medication Reconciliation (MedRec) is an essential part of safe medication management and plays a key role in ensuring patient safety. A variety of methods and a number of different healthcare disciplines can be involved in the MedRec process and the timing and location of conducting MedRec can vary. In an effort to streamline the process in ambulatory oncology new patient clinics, a pilot of an alternative approach was undertaken whereby pharmacists with advanced prescribing privileges completed MedRec with patients prior to their clinic visit. Evaluation of the pilot was completed through the collection of various metrics, a pharmacist focus group, healthcare staff and patient surveys. Overall the evaluation indicated that there are multiple factors to consider regarding the timing and method of MedRec completion. The various phases of the pilot demonstrated that flexibility to the process is key and ongoing efforts are required at reducing duplication.
Asunto(s)
Conciliación de Medicamentos , Farmacéuticos , Atención Ambulatoria , Instituciones de Atención Ambulatoria , Humanos , Seguridad del PacienteRESUMEN
The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.
Asunto(s)
Oncología Médica/normas , Neoplasias/terapia , Grupo de Atención al Paciente/organización & administración , Sociedades Farmacéuticas , Antineoplásicos/uso terapéutico , Educación en Farmacia , Adhesión a Directriz , Humanos , Atención al Paciente , Seguridad del Paciente , Servicios Farmacéuticos , Farmacéuticos , Técnicos de Farmacia , Investigación , EspecializaciónRESUMEN
Increasingly stringent pharmacy standards for preparation of sterile products necessitated a review of the feasibility of continuing to maintain chemotherapy sterile production facilities across the provincial cancer programme. The concept of centrally produced chemotherapy that could be shipped to various locations as a remote service delivery model was explored. Key planning principles were established and detailed processes were developed to test this change in service delivery at one small cancer centre. Following the successful implementation and evaluation of the remote service delivery model at one centre, the programme was rolled out to an additional four centres.
Asunto(s)
Antineoplásicos/administración & dosificación , Servicios Farmacéuticos/organización & administración , Atención a la Salud , HumanosRESUMEN
Chemotherapy checking is a complex task and requires a high level of alertness and attention to detail. Learning tools are required to teach the fundamental principles of chemotherapy checking. In conjunction with a graphic design team and with input from Human Factors specialists, an online chemotherapy checking training module was created. A variety of learning methods were incorporated including pre-reading, hands on training, case scenarios, and exam questions. The necessary skills to safely complete chemotherapy checking can be enhanced by the use of this training module.
Asunto(s)
Antineoplásicos/normas , Competencia Clínica , Instrucción por Computador , Humanos , Alcance de la PrácticaRESUMEN
Following a review of a chemotherapy medication adverse event where the incorrect medication was prepared by a pharmacy, a number of steps were taken to review the literature and best practice information related to checking processes for the preparation of parenteral chemotherapy. Concepts such as identification of critical stop check points, independent double checks, and human factors principles were reviewed and incorporated into newly designed chemotherapy preparation worksheets with embedded checklists. Usability testing and staff feedback during implementation revealed a number of key learning points that resulted in additional work to further improve the chemotherapy worksheets with embedded checklists and highlighted the need for a culture of continuous quality improvement.
Asunto(s)
Administración Intravenosa/efectos adversos , Antineoplásicos/administración & dosificación , Errores de Medicación/prevención & control , Lista de Verificación/métodos , Humanos , Servicios Farmacéuticos , SeguridadRESUMEN
PURPOSE: Intravenous (IV) compounding safety has garnered recent attention as a result of high-profile incidents, awareness efforts from the safety community, and increasingly stringent practice standards. New research with more-sensitive error detection techniques continues to reinforce that error rates with manual IV compounding are unacceptably high. In 2014, our team published an observational study that described three types of previously unrecognized and potentially catastrophic latent chemotherapy preparation errors in Canadian oncology pharmacies that would otherwise be undetectable. We expand on this research and explore whether additional potential human failures are yet to be addressed by practice standards. METHODS: Field observations were conducted in four cancer center pharmacies in four Canadian provinces from January 2013 to February 2015. Human factors specialists observed and interviewed pharmacy managers, oncology pharmacists, pharmacy technicians, and pharmacy assistants as they carried out their work. Emphasis was on latent errors (potential human failures) that could lead to outcomes such as wrong drug, dose, or diluent. RESULTS: Given the relatively short observational period, no active failures or actual errors were observed. However, 11 latent errors in chemotherapy compounding were identified. In terms of severity, all 11 errors create the potential for a patient to receive the wrong drug or dose, which in the context of cancer care, could lead to death or permanent loss of function. Three of the 11 practices were observed in our previous study, but eight were new. Applicable Canadian and international standards and guidelines do not explicitly address many of the potentially error-prone practices observed. CONCLUSION: We observed a significant degree of risk for error in manual mixing practice. These latent errors may exist in other regions where manual compounding of IV chemotherapy takes place. Continued efforts to advance standards, guidelines, technological innovation, and chemical quality testing are needed.
Asunto(s)
Antineoplásicos/efectos adversos , Antineoplásicos/química , Composición de Medicamentos , Errores de Medicación , Neoplasias/epidemiología , Administración Intravenosa , Antineoplásicos/administración & dosificación , Canadá/epidemiología , Estudios de Seguimiento , Humanos , Neoplasias/tratamiento farmacológico , Farmacéuticos , Servicio de Farmacia en Hospital/normas , Medición de Riesgo , Factores de RiesgoRESUMEN
OBJECTIVE: To continue with workplace contamination monitoring in the Alberta Cancer Board (ACB) pharmacy practice environment. SETTING: The ACB in the Canadian province of Alberta which includes two public tertiary centers and 19 associated community satellite sites based around the province in existing hospitals. METHODS: After the completion of a Phase 1 and Phase 11 study,(1) which investigated the feasibility of routine monitoring of antineoplastic agent contamination in the pharmacy practice environment, it was decided to launch a Phase III study. The Phase III study would be done at the Cross Cancer Institute in the main pharmacy department as well as at a brand new satellite pharmacy within the CCI hospital. Samples would be taken in these areas as well as on the outer exterior of latex gloves worn to prepare cyclophosphamide and other antineoplastics. RESULTS: The result determined that the area in front of the biological safety cabinet in the main CCI pharmacy department as well as the exterior of the latex gloves showed evidence of cyclophosphamide contamination. The results from the sample taken in the new satellite pharmacy showed no evidence of cyclophosphamide contamination. CONCLUSION: results from this study prompted a decision to launch a Phase IV study to determine the feasibility within our network, for routine monitoring as well as sampling throughout the clean room beyond the BSC.
Asunto(s)
Antineoplásicos/análisis , Ciclofosfamida/análisis , Monitoreo del Ambiente/métodos , Contaminación Ambiental/prevención & control , Exposición Profesional/prevención & control , Servicio de Farmacia en Hospital , Alberta , Guantes ProtectoresRESUMEN
PURPOSE: To provide a current review of the literature related to chemotherapy induced diarrhea (CID), including clinical assessment, recommended management guidelines and investigational pharmacological approaches for the prevention and treatment of CID. DATA SOURCES: A search of MEDLINE, PubMed, EMBASE, Cochrane Library, International Pharmaceutical Abstracts, and Web of Science (1996-2006) databases was conducted using terms such as: chemotherapy, diarrhea, diarrhoea, and irinotecan. Appropriate references from selected articles were also used. The search engine, Google, provided further access to information. DATA EXTRACTION: The retrieved literature was reviewed to include all articles pertaining to the pathophysiology, assessment and management of CID. DATA SYNTHESIS: Diarrhea is a debilitating and potentially life-threatening side effect associated with many chemotherapeutic agents. Despite the high incidence and severity of CID, it is often under recognized and poorly managed. A multidisciplinary panel recently updated recommended practice guidelines for the assessment and management of CID. Prompt and aggressive intervention is important in order to minimize the negative consequences of CID, such as dehydration, which may cause interruptions in optimal clinical outcomes or may lead to life-threatening sequelae. Further investigation into the pathophysiology of CID may allow for more directed approaches in the prophylaxis and treatment of CID.
Asunto(s)
Antineoplásicos/efectos adversos , Diarrea/inducido químicamente , Neoplasias/tratamiento farmacológico , Antidiarreicos/uso terapéutico , Diarrea/fisiopatología , Diarrea/terapia , Humanos , Farmacéuticos/organización & administración , Guías de Práctica Clínica como Asunto , Rol Profesional , Factores de Riesgo , Índice de Severidad de la EnfermedadRESUMEN
STUDY OBJECTIVE: To investigate the feasibility of routine monitoring for workplace antineoplastic agent contamination in the Alberta Cancer Board (ACB) pharmacy practice environment. SETTING: The ACB in the Canadian province of Alberta, which includes two public tertiary centres and 17 associated community satellite sites based around the province in existing hospitals. METHODS: Obtained organizational support and input prior to launching the feasibility study (Phase I). Samples were analysed for a common cytotoxic agent - cyclophosphamide. Surfaces chosen were within the biological safety cabinets, workplace counter tops and on external surfaces of vials provided by manufacturers. Blank samples and known contaminated controls were included in Phase I to reconfirm the methodology in a previously published study. Feasibility aspects of logistics and financial expenses were examined. A second phase (Phase II) was completed to test other areas of the pharmacy and vials, with blank samples included to reconfirm previously mentioned methodology. RESULTS: The results determined that the samples tested were below acceptable detection limits with the exception of the known contaminated sample (Phase I) and exterior surfaces of vials (Phase II). CONCLUSION: This project has increased staff awareness of the sources for antineoplastic agent workplace contamination. Some practice changes were instituted during the project itself. Logistics and expenses were realistic for routine monitoring to be adopted.